Journal of Clinical Oncology
Articles in this Issue
Surveillance after complete response (CR) to first-line chemotherapy (chemo) in non-seminomatous germ-cell tumor (NSGCT).
599 Background: Management of NSGCT following CR after first-line chemo remains variable across institutions. Recent data...
Development of a non-muscle invasive bladder cancer (NMIBC) genomic score (NGS) to predict early BCG failure.
850 Background: Although BCG is the standard of care for high-grade (HG)-NMIBC, half of patients recur and 25% progress to...
Differential performance of immune-combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma (mRCC) with sarcomatoid features (sRCC) (Meet-URO 33 analysis).
449 Background: The treatment landscape of mRCC has deeply evolved with the advent of 1 st...
Demographic and socioeconomic disparities in early-onset vs. late-onset bladder cancer: A cross-sectional study in the NIH All of Us research program.
657 Background: Bladder cancer typically presents after age 60, but cases diagnosed before age 60 (early-onset) may show d...
Characteristics, treatment (tx) patterns and outcomes in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC): A retrospective cohort study in England.
665 Background: Real-world data are needed to improve the understanding of the clinical management of la/mUC and associate...
Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).
545 Background: The LITESPARK-013 study (NCT04489771) showed similar efficacy and safety between 200 mg and 120 mg (approv...
Predictive value of Gleason pattern 4 length on adverse surgical pathology and oncologic outcomes.
348 Background: Gleason grade group (GG) has traditionally guided prostate cancer risk stratification. Emerging evidence s...
Racial and ethnic disparities in variant histology bladder cancer: Insights from SEER 2000–2021.
651 Background: Variant histology bladder cancer (VHBC) - including squamous, plasmacytoid, neuroendocrine/small cell, sar...
KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.
557 Background: Kidney Injury Molecule-1 (KIM-1) has emerged as a promising biomarker in clear cell renal cell carcinoma (...
Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study.
454 Background: Immune checkpoint inhibitor (ICI)-based combination therapy has become the standard of care for advanced r...
Integrating pharmacists into uro-oncology care: Evaluation of patient satisfaction and well-being.
714 Background: Uro-oncology patients are particularly vulnerable due to age-related comorbidity and polymedication while...
KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).
505 Background: The addition of novel mechanisms of action to established treatment strategies may further improve outcome...
Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.
170 Background: Androgen receptor (AR) targeting strategies have demonstrated clinical impact in high-risk BCR (e.g., PSA...
Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network.
706 Background: Enfortumab vedotin plus pembrolizumab (EV+P) has demonstrated superior OS compared to platinum-based chemo...
Bridging trial and practice: Real-world data of adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.
710 Background: Adjuvant immune checkpoint inhibition with nivolumab has demonstrated efficacy in randomized clinical tria...
Machine learning-based phenotyping and trial emulation to identify checkpoint inhibitor responders in advanced urothelial cancer.
698 Background: Randomized trials of first-line single-agent checkpoint inhibitors (CPIs) in advanced urothelial cancer (a...
A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma.
492 Background: The incidence of brain metastases(mets) in patients (pts) with advanced renal cell carcinoma (aRCC) is app...
Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.
TPS2 Background: Pts with relapsed/refractory epNEC have poor outcomes with currently available therapies. DLL3 is express...
The overlooked culprit: Tumor size in muscle-invasive bladder cancer.
836 Background: Bladder cancer staging has historically focused solely on the depth of invasion, and the impact of tumor s...
Long-term outcomes with radium-223 in metastatic castration resistant prostate cancer: US patient subset of the 10-year REASSURE global study.
85 Background: Radium-223 (Ra-223) is approved for patients (pts) with metastatic castration-resistant prostate cancer (mC...
ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.
821 Background: Nectin-4 targeting antibody drug conjugate (ADC) enfortumab vedotin (EV), in combination with pembrolizuma...
Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).
800 Background: EVP is active in aUC; however, biomarkers predicting early benefit are lacking. ctDNA is a noninvasive mar...
PERSIAN trial (NCT03449719): Predictive features of complete biochemical response within a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.
157 Background: Apalutamide+androgen deprivation therapy (ADT) currently represents one of the accepted standards of care...
Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure.
101 Background: Lu is a prostate-specific membrane antigen (PSMA)-targeting radioligand therapy. Its approval was recently...
TP53 mutations (TP53mut) as a predictive biomarker for lutetium-177-PSMA (Lu-PSMA) vs. docetaxel benefit in post-androgen receptor pathway inhibitors (ARPI) metastatic castration-resistant prostate cancer (mCRPC).
28 Background: Predictive biomarkers are needed to help guide Lu-PSMA vs. taxane use in post-ARPI mCRPC. Randomized trials...